Anebulo Pharmaceuticals, Inc.

OTC: ANEB · Healthcare · Biotechnology

PublicHQ Lakeway, TX · TravisCIK 0001815974Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 44DQ —GM —SS 26

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.5M

Employees

as of 2026-08-21

Market cap

$14.3M

as of 2026-08-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$8.5M-$8.5M2025

Operating income-$9.2M-$9.2M2025

Total assets$12.1M$12.1M2025

Liabilities$487.7k$487.7k2025

Equity$11.7M$11.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Anebulo Pharmaceuticals, Inc.’s financial profile?

Anebulo Pharmaceuticals, Inc. earned -$8.5M in FY2025 net income.

Peers · Healthcare

CS Diagnostics Corp.——BioVie Inc.——Passage Bio, Inc.——Intensity Therapeutics, Inc.——IN8bio, Inc.——Brainstorm Cell Therapeutics Inc.——

Neighbors

Travis →

Tesla, Inc.$94.8B69B Oracle Corporation$67.4B86A CrowdStrike Holdings, Inc.$4.8B63C Digital Realty Trust, Inc.$6.1B70B SailPoint, Inc.$1.1B50D Silicon Laboratories Inc.$784.8M71B

Key facts

CEORichard Anthony Cunningham

SectorHealthcare

IndustryBiotechnology

HeadquartersLakeway, TX

ExchangeOTC: ANEB

Employees3

IPO date2021-05-07

Latest filings

10-Q2026-02-12 8-K2026-02-12 8-K2026-02-06 8-K2026-01-29 8-K2026-01-27 8-K2025-12-22 10-Q2025-11-13 8-K2025-11-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.